ZVRA – zevra therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]
Zevra Therapeutics (NASDAQ:ZVRA) was given a new $26.00 price target on by analysts at HC Wainwright.
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
Form 4 ZEVRA THERAPEUTICS, INC. For: Dec 31 Filed by: Clifton R. LaDuane
Form 8-K ZEVRA THERAPEUTICS, INC. For: Dec 11
Form 4 ZEVRA THERAPEUTICS, INC. For: Dec 02 Filed by: Secor Alicia
Form 3 ZEVRA THERAPEUTICS, INC. For: Dec 02 Filed by: Secor Alicia
Form 8-K ZEVRA THERAPEUTICS, INC. For: Nov 26
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.